Meyka AI API is live for developers.Start building.
Advertisement
Travere Therapeutics, Inc.

Travere Therapeutics, Inc. (TVTX) Stock Overview

Explore Travere Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

TVTXNASDAQ
HealthcareBiotechnology
$45.81
$0.37(0.80%)
U.S. Market opens in 59h 13m
Advertisement

Travere Therapeutics, Inc. (TVTX)

Meyka AI Score

Z

Key Financials

Market Cap4.3B
P/E Ratio-197.94
EPS (TTM)$-0.50
ROE-0.27%
Fundamental Analysis

AI Price Forecasts

1 Month$23.42
3 Months$28.18
1 Year Target$42.36

TVTX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Travere Therapeutics, Inc. (TVTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 58.11, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $42.36.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -197.94 and a market capitalization of 4.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.84%
5-Day Change
-4.12%
1-Month Change
2.21%
3-Month Change
67.67%
6-Month Change
30.83%
Year-to-Date (YTD) Change
19.84%
1-Year Change
211.07%
3-Year Change
143.43%
5-Year Change
219.09%
All-Time (Max) Change
2952.67%

Contact Information

888 969 7879
3611 Valley Centre Drive, San Diego, CA, 92130

Company Facts

385 Employees
IPO DateNov 8, 2012
CountryUS
Actively Trading

Frequently Asked Questions